BORA LIM

BORA LIM

Baylor College of Medicine

H-index: 32

North America-United States

About BORA LIM

BORA LIM, With an exceptional h-index of 32 and a recent h-index of 30 (since 2020), a distinguished researcher at Baylor College of Medicine, specializes in the field of Breast Cancer, molecular biology, novel therapeutics, triple negative breast cancer, inflammatory.

His recent articles reflect a diverse array of research interests and contributions to the field:

Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy

High brain relapse rates in stage III triple negative inflammatory breast cancer are independent of systemic therapy

Normal breast tissues harbor rare populations of aneuploid epithelial cells

Decoding the archetypes and eco-hubs of triple-negative breast cancer in responses to chemotherapy

Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

Abstract GS01-08: CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer

Abstract PO2-14-11: Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment

Abstract PO5-06-02: Phase II Trial of Combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab and Eribulin (AE) in patients with metastatic inflammatory …

BORA LIM Information

University

Position

___

Citations(all)

4469

Citations(since 2020)

3895

Cited By

1523

hIndex(all)

32

hIndex(since 2020)

30

i10Index(all)

76

i10Index(since 2020)

70

Email

University Profile Page

Google Scholar

BORA LIM Skills & Research Interests

Breast Cancer

molecular biology

novel therapeutics

triple negative breast cancer

inflammatory

Top articles of BORA LIM

Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy

Clinical Cancer Research

2024/5/1

High brain relapse rates in stage III triple negative inflammatory breast cancer are independent of systemic therapy

Cancer Research

2024/3/22

Normal breast tissues harbor rare populations of aneuploid epithelial cells

Cancer Research

2024/3/22

Decoding the archetypes and eco-hubs of triple-negative breast cancer in responses to chemotherapy

Cancer Research

2024/3/22

Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

JCO Precision Oncology

2024/3

Abstract GS01-08: CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer

Cancer Research

2024/5/2

Abstract PO2-14-11: Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment

Cancer Research

2024/5/2

Abstract PO5-06-02: Phase II Trial of Combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab and Eribulin (AE) in patients with metastatic inflammatory …

Cancer Research

2024/5/2

Abstract PO1-29-01: Single agent and combinatorial efficacy with imipridone ONC206 via inhibition of mitochondrial function in preclinical models of chemorefractory triple …

Cancer Research

2024/5/2

Bora Lim
Bora Lim

H-Index: 22

Michael Lewis
Michael Lewis

H-Index: 22

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Investigational New Drugs

2023/6

Wei Yang
Wei Yang

H-Index: 22

Bora Lim
Bora Lim

H-Index: 22

Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?

Clinical breast cancer

2023/6/1

Reprogramming of the preinvasive breast microenvironment identified by spatial nucleus barcoding

Cancer Research

2023/4/4

Tumor cell total mRNA level predicts disease progression across multi-ethnic patient cohorts with triple-negative breast cancer

Cancer Research

2023/4/4

Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment

Oncogene

2023/3/30

Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies

Science Advances

2023/3/29

Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation

Cell Metabolism

2023/8/8

Association of cyclooxygenase-2 expression with endoplasmic reticulum stress and autophagy in triple-negative breast cancer

PloS one

2023/8/4

Sungwook Jung
Sungwook Jung

H-Index: 9

Bora Lim
Bora Lim

H-Index: 22

Phenotypic plasticity in circulating tumor cells is associated with poor response to therapy in metastatic breast cancer patients

Cancers

2023/3/6

Abstract P6-11-14: Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment

Cancer Research

2023/3/1

See List of Professors in BORA LIM University(Baylor College of Medicine)

Co-Authors

academic-engine